Adverse events to monoclonal antibodies used for cancer therapy: Focus on hypersensitivity responses.
about
Understanding the Supersensitive Anti-Drug Antibody Assay: Unexpected High Anti-Drug Antibody Incidence and Its Clinical RelevanceFc glycans of therapeutic antibodies as critical quality attributesTrial Watch: Immunomodulatory monoclonal antibodies for oncological indicationsCutaneous complications of molecular targeted therapy used in oncologyGlypican-3 Targeting Immunotoxins for the Treatment of Liver CancerIgE immunotherapy against cancerTrial Watch: Proteasomal inhibitors for anticancer therapyIrigenin, a novel lead from Western Himalayan chemiome inhibits Fibronectin-Extra Domain A induced metastasis in Lung cancer cells.Current knowledge and future research directions in treatment-related second primary malignancies.Preclinical screening for acute toxicity of therapeutic monoclonal antibodies in a hu-SCID model.Novel immune checkpoint blocker approved for the treatment of advanced melanomaInhibitory receptors as targets for cancer immunotherapySafety and tolerability of an anti-CD19 monoclonal antibody, MEDI-551, in subjects with systemic sclerosis: a phase I, randomized, placebo-controlled, escalating single-dose study.Why man's best friend, the dog, could also benefit from an anti-HER-2 vaccineCanonical and new generation anticancer drugs also target energy metabolism.Side effects of cytokines approved for therapy.Chimeric fusion proteins used for therapy: indications, mechanisms, and safety.Subsequent primary malignancies after diffuse large B-cell lymphoma in the modern treatment era.Managing the oncologic patient with suspected pneumonia in the intensive care unit.Incidence of infusion reactions to anti-neoplastic agents in early phase clinical trials: The MD Anderson Cancer Center experience.Immunotherapy for the treatment of colorectal tumors: focus on approved and in-clinical-trial monoclonal antibodies.Safety Profile of Anticancer and Immune-Modulating Biotech Drugs Used in a Real World Setting in Campania Region (Italy): BIO-Cam Observational StudyFunctionally Active Fc Mutant Antibodies Recognizing Cancer Antigens Generated Rapidly at High Yields.Adverse cardiac events to monoclonal antibodies used for cancer therapy: The risk of Kounis syndrome.Countering immunotoxin immunogenicity.Drug Hypersensitivity and Anaphylaxis in Cancer and Chronic Inflammatory Diseases: The Role of Desensitizations.Safety of shortened infusion times for combined ipilimumab and nivolumab.Evaluation of Next-Generation Anti-CD20 Antibodies Labeled with Zirconium 89 in Human Lymphoma Xenografts.Management of infusion reactions to systemic anticancer therapy: ESMO Clinical Practice Guidelines.Mutual Destruction of Deep Lung Tumor Tissues by Nanodrug-Conjugated Stealth Mesenchymal Stem Cells.Extensive toxic epidermal necrolysis following brentuximab vedotin administration
P2860
Q26747193-A64D2D99-8163-468A-AD78-223F813745CAQ26799266-F9059087-D429-4EB3-9D8F-639E35710173Q26996518-5F4425F0-9F55-45F9-985F-BCFB88B96A4BQ28070095-4DDCC023-1126-48DD-B4C9-18ECCE14C71FQ28077270-985163AB-2DB6-4ED6-A658-EFD6B598C4A3Q28081223-4ACB9967-091D-4C6B-8093-6AE5DEE8FE32Q28082910-FE89730C-F89F-42BC-A848-3849ADD53DFBQ30828838-1A313F9F-791C-4F1A-A4FB-3D721042F38FQ34604460-770C6C1B-1B1A-4407-B013-2CC0CD3FCAAAQ34803897-E116B927-53EC-4B3E-AB5B-C1F6AB42BD22Q34936394-E291679C-C254-4062-9F6F-4B481B73F759Q35995373-A2559CAC-82F5-471F-9E60-671F175D2BE0Q36975931-5B630F50-EB66-4B88-9D90-90D1C58ED13FQ37289389-1515BBBB-6785-4AFA-BF46-FAC5E3F5918AQ38208982-31E3BF56-A59F-452D-B07C-8397FF1F3EE3Q38255698-81BD89C7-52A1-4E59-8A0E-D89C75EA6676Q38400396-A704CBA1-2142-4C94-9954-62E854EFC9D8Q38679176-553EBEA8-55E8-4371-B4CA-39F6D64E5A45Q38940456-E915147B-E5C1-4236-96C3-DBF6C345A467Q38968266-08FEF3BB-18F5-4F0C-8AE5-EE466AC8490BQ39110385-5B998F9C-9C29-4FCE-828A-1766882BC22AQ41439263-BDD0DFC2-6659-472A-812A-795B1B11611AQ41673094-D3FC7ED5-646E-4A5A-9A51-6C5BA669F75FQ42078094-419F2644-5666-49F8-A168-573C46169176Q42573903-9FEB8D48-5398-426C-B61C-1852D9F24BF2Q44842257-978B54FC-C772-4BB1-9A49-739435A2BA0FQ49501208-A325367C-5D71-4333-BA69-75E0924C9AD3Q49953473-60F1EB91-383D-4C1B-AAF5-FE60F18252D7Q50205188-70252AC4-B165-4652-ABEF-E36A887CAB74Q55155227-35FC4BF5-B35D-41DA-8875-26C088106BA6Q59314779-EAFCD1FB-DCE8-4E74-AF69-FD0F3190D65B
P2860
Adverse events to monoclonal antibodies used for cancer therapy: Focus on hypersensitivity responses.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
Adverse events to monoclonal a ...... on hypersensitivity responses.
@en
Adverse events to monoclonal a ...... on hypersensitivity responses.
@nl
type
label
Adverse events to monoclonal a ...... on hypersensitivity responses.
@en
Adverse events to monoclonal a ...... on hypersensitivity responses.
@nl
prefLabel
Adverse events to monoclonal a ...... on hypersensitivity responses.
@en
Adverse events to monoclonal a ...... on hypersensitivity responses.
@nl
P2860
P356
P1433
P1476
Adverse events to monoclonal a ...... on hypersensitivity responses.
@en
P2093
Brian A Baldo
P2860
P304
P356
10.4161/ONCI.26333
P577
2013-10-17T00:00:00Z